Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
How long after a successful parathyroid surgery would you reassess bone density in a patient with severe osteoporosis ?
Related Questions
Would you use a parathyroid hormone analog for treatment of osteoporosis in a patient with mildly elevated AlkPhos of unclear etiology?
Under what circumstances would you consider a bone biopsy in the workup of renal osteodystrophy?
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
Which method provides a more accurate assessment of hypercalciuria: 24-hour urinary calcium excretion or the spot urine calcium-to-creatinine ratio?
How do you counsel patients on the risks and benefits of strontium supplements for osteoporosis management?
Do you prefer kidney ultrasound or a non-contrast CT scan to evaluate for nephrolithiasis in an asymptomatic patient with primary hyperparathyroidism?
Does parathyroidectomy for primary hyperparathyroidism provide metabolic benefits, such as lowering diabetes or cardiovascular disease risk?
Would you order a repeat DEXA scan 1 year later for a kidney transplant patient who had an initial DEXA scan within the first 6 months post-transplant showing osteopenia but no history of fractures, and who has been stable on glucocorticoid-free immunosuppressive therapy?
How long should a patient be treated with a bisphosphonate after a course of an anabolic medication has been completed?
In a patient with severe osteoporosis (T-score -3.9) and multiple vertebral fractures in the setting of multiple myeloma with bone involvement, would you consider adding an anabolic agent such as romosozumab or teriparatide despite concerns about osteosarcoma risk?
